The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality
Launched by THE CLEVELAND CLINIC · Aug 11, 2025
Trial Information
Current as of August 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain diabetes medications called GLP-1 and GIP agonists affect the quality of bowel preparation before a colonoscopy. Bowel preparation is the process of cleaning out your colon so doctors can get a clear view during the colonoscopy. The study wants to find out if these medications make bowel preparation less effective, and whether stopping or continuing a single dose of these drugs before the procedure changes the results or the risk of complications like stomach problems.
Adults 18 years and older who are already taking a stable dose of a GLP-1 or GIP agonist and are scheduled for a colonoscopy may be eligible to join. Participants will follow a specific bowel cleansing routine and may be asked to either hold or continue their medication before the procedure. The study will then compare the quality of bowel cleaning and any complications between these groups. This research could help doctors give better advice on managing these medications before colonoscopies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patient (Age 18 years or older)
- • Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy
- • Using a GLP-1 or GIP agonist at a stable dose for at least one month
- Exclusion Criteria:
- • Unable to provide informed consent, e.g., dementia
- • Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy)
- * Risk factors for inadequate bowel preparation besides diabetes and obesity with a likelihood ratio of 1.6 or greater:
- • 1. Cirrhosis
- • 2. Parkinson's disease
- • 3. Dementia
- • 4. Tricyclic antidepressant use
- • 5. Opioid use
- • 6. Gastroparesis\* or suspected gastric outlet obstruction on pre-procedure imaging (\*defined based on a documented 4-hour solid phase gastric emptying study or prior history of retained gastric contents during upper endoscopy)
- • 7. Previous colorectal surgery
- • 8. Prior history of inadequate bowel preparation
About The Cleveland Clinic
The Cleveland Clinic is a renowned nonprofit academic medical center based in Cleveland, Ohio, recognized for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, the Cleveland Clinic leverages its multidisciplinary expertise and state-of-the-art facilities to conduct groundbreaking studies aimed at improving patient outcomes across a wide range of medical conditions. With a strong emphasis on patient-centered care, the institution fosters collaboration among researchers, clinicians, and patients to explore new treatments and therapies, contributing significantly to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Weston, Florida, United States
Cleveland, Florida, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported